Featured Press Releases

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx debuts a new e-commerce platform, starting with Opill®

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

Alcami to expand lab services at Durham, NC facility to meet rising biologics demand

  • 22 Oct 2025

Alcami Corporation a leading U.S.-based contract development and manufacturing organization...

RiDYMO® develops a cyclic peptide targeting the

RiDYMO® develops a cyclic peptide targeting the "undruggable" β-catenin in just two months

First National Campaign Launched by Trauma Intervention Programs (TIP)

First National Campaign Launched by Trauma Intervention Programs (TIP)

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

BerGenBio selects 2nd dose in Phase 2a STK11m Non-Small Cell Lung Cancer trial.

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

SHARx Focuses on Rx Continuity for Employers and Patients as Customs Requirements Change

SHARx Focuses on Rx Continuity for Employers and Patients as Customs Requirements Change

  • SHARx
  • 28 Sep 2026
Zifo Unveils Vision for an AI-Driven Scientific Semantic Layer in Biopharma

Zifo Unveils Vision for an AI-Driven Scientific Semantic Layer in Biopharma

  • Zifo
  • 28 Sep 2026
ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

  • ImmunoScape Pte. Ltd.
  • 23 Sep 2026
LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

  • LEVEL
  • 22 Sep 2026
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

  • Padagis
  • 21 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.